Literature DB >> 19002136

Women with a history of preeclampsia should be monitored for the onset and progression of chronic kidney disease.

Takayuki Hamano1.   

Abstract

This Practice Point commentary discusses a recent paper in which Vikse et al. demonstrated that history of preeclampsia is a marker for an increased risk of end-stage renal disease (ESRD). Among women with preeclampsia, giving birth to a low-birth-weight or preterm infant further increased the relative risk of ESRD, which suggests that more-severe preeclampsia might be a marker for an even higher risk of ESRD. Although the precise mechanisms for the association between preeclampsia and ESRD were not demonstrated, the common risk factors of preeclampsia and chronic kidney disease might explain these observations; alternatively, preeclampsia itself might induce renal injury by suppressing the activity of renoprotective angiogenic factors. This commentary emphasizes that although the absolute risk of developing ESRD is low, women with a history of preeclampsia should undergo renal follow-up (including estimation of glomerular filtration rate, measurement of blood pressure and quantification of proteinuria), a practice which might also decrease risk of cardiovascular disease.

Entities:  

Year:  2008        PMID: 19002136     DOI: 10.1038/ncpneph0991

Source DB:  PubMed          Journal:  Nat Clin Pract Nephrol        ISSN: 1745-8323


  8 in total

1.  Adverse perinatal outcome and later kidney biopsy in the mother.

Authors:  Bjørn Egil Vikse; Lorentz M Irgens; Leif Bostad; Bjarne M Iversen
Journal:  J Am Soc Nephrol       Date:  2006-01-18       Impact factor: 10.121

2.  Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases.

Authors:  Vera Eremina; Manish Sood; Jody Haigh; András Nagy; Ginette Lajoie; Napoleone Ferrara; Hans-Peter Gerber; Yamato Kikkawa; Jeffrey H Miner; Susan E Quaggin
Journal:  J Clin Invest       Date:  2003-03       Impact factor: 14.808

3.  Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia.

Authors:  Sharon E Maynard; Jiang-Yong Min; Jaime Merchan; Kee-Hak Lim; Jianyi Li; Susanta Mondal; Towia A Libermann; James P Morgan; Frank W Sellke; Isaac E Stillman; Franklin H Epstein; Vikas P Sukhatme; S Ananth Karumanchi
Journal:  J Clin Invest       Date:  2003-03       Impact factor: 14.808

4.  Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria.

Authors:  Hikaru Sugimoto; Yuki Hamano; David Charytan; Dominic Cosgrove; Mark Kieran; Akulapalli Sudhakar; Raghu Kalluri
Journal:  J Biol Chem       Date:  2003-01-21       Impact factor: 5.157

Review 5.  How should women with pre-eclampsia be followed up? New insights from mechanistic studies.

Authors:  Alexandre Hertig; Suzanne Watnick; Helena Strevens; Henri Boulanger; Nadia Berkane; Eric Rondeau
Journal:  Nat Clin Pract Nephrol       Date:  2008-07-15

6.  Decreased flow-mediated dilation is present 1 year after a pre-eclamptic pregnancy.

Authors:  Rangeen Rafik Hamad; Maria J Eriksson; Angela Silveira; Anders Hamsten; Katarina Bremme
Journal:  J Hypertens       Date:  2007-11       Impact factor: 4.844

7.  VEGF inhibition and renal thrombotic microangiopathy.

Authors:  Vera Eremina; J Ashley Jefferson; Jolanta Kowalewska; Howard Hochster; Mark Haas; Joseph Weisstuch; Catherine Richardson; Jeffrey B Kopp; M Golam Kabir; Peter H Backx; Hans-Peter Gerber; Napoleone Ferrara; Laura Barisoni; Charles E Alpers; Susan E Quaggin
Journal:  N Engl J Med       Date:  2008-03-13       Impact factor: 91.245

8.  Preeclampsia and the risk of end-stage renal disease.

Authors:  Bjørn Egil Vikse; Lorentz M Irgens; Torbjørn Leivestad; Rolv Skjaerven; Bjarne M Iversen
Journal:  N Engl J Med       Date:  2008-08-21       Impact factor: 91.245

  8 in total
  2 in total

Review 1.  Risk of cardiovascular disease, end-stage renal disease, and stroke in postpartum women and their fetuses after a hypertensive pregnancy.

Authors:  Mark W Cunningham; Babbette LaMarca
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2018-06-13       Impact factor: 3.619

2.  Angiotensin II type 1 receptor agonistic autoantibody blockade improves postpartum hypertension and cardiac mitochondrial function in rat model of preeclampsia.

Authors:  George W Booz; Daniel Kennedy; Michael Bowling; Taprieka Robinson; Daniel Azubuike; Brandon Fisher; Karen Brooks; Pooja Chinthakuntla; Ngoc H Hoang; Jonathan P Hosler; Mark W Cunningham
Journal:  Biol Sex Differ       Date:  2021-11-02       Impact factor: 5.027

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.